APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Narcolepsy Drug

Narcolepsy is a long-term neurological disorder that involves a decreased ability to regulate sleep-wake cycles. Symptoms include periods of excessive daytime sleepiness that usually last from seconds to minutes and may occur at any time. About 70% of people also experience episodes of sudden loss of muscle strength, known as cataplexy. These spells can be brought on by strong emotions. Less commonly, there may be inability to move or vivid hallucinations while falling asleep or waking up. People with narcolepsy tend to sleep about the same number of hours per day as people without, but the quality of sleep tends to be worse.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Narcolepsy is a long-term neurological disorder that involves a decreased ability to regulate sleep-wake cycles. Symptoms include periods of excessive daytime sleepiness that usually last from seconds to minutes and may occur at any time. About 70% of people also experience episodes of sudden loss of muscle strength, known as cataplexy. These spells can be brought on by strong emotions. Less commonly, there may be inability to move or vivid hallucinations while falling asleep or waking up. People with narcolepsy tend to sleep about the same number of hours per day as people without, but the quality of sleep tends to be worse.

The narcolepsy drug is the drug to treat narcolepsy.

Selected research

Market Outlook & Growth Opportunities

Global Narcolepsy Drug Market Outlook and Growth Opportunities 2026

Report ID 17401572042 January 2026192 pages

Choose your research edition.

Industry ResearchNarcolepsy Drug Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Narcolepsy Drug Industry Growth and Trends Forecast to 203279 pages · $3,450 USDMarket StructureGlobal Narcolepsy Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032170 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Narcolepsy Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Narcolepsy Drug Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

Narcolepsy is a long-term neurological disorder that involves a decreased ability to regulate sleep-wake cycles. Symptoms include periods of excessive daytime sleepiness that usually last from seconds to minutes and may occur at any time. About 70% of people also experience episodes of sudden loss of muscle strength, known as cataplexy. These spells can be brought on by strong emotions. Less commonly, there may be inability to move or vivid hallucinations while falling asleep or waking up. People with narcolepsy tend to sleep about the same number of hours per day as people without, but the quality of sleep tends to be worse.

The narcolepsy drug is the drug to treat narcolepsy.

Market competition is concentrated. Jazz Pharmaceuticals, Teva Pharmaceutical, Novartis and Mylan. are the leaders of the industry, with about 91% market shares.

Read the full market overview

Europe is the largest consumption place, with a consumption market share nearly 58%. Following Europe, USA is the second largest consumption place with the consumption market share of 29%.

This report provides an overview of the global Narcolepsy Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Narcolepsy Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Narcolepsy Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Narcolepsy Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Narcolepsy Drug Segment by Company

Jazz Pharmaceuticals

Teva Pharmaceutical

Novartis

Mylan

Narcolepsy Drug Segment by Type

Antioxidants Type

Stimulants Type

Others

Narcolepsy Drug Segment by Application

Daytime Extreme Sleepiness

Cataplexia

Others

Narcolepsy Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Narcolepsy Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Narcolepsy Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Narcolepsy Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Narcolepsy Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Narcolepsy Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Narcolepsy Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Narcolepsy Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Narcolepsy Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Narcolepsy Drug industry.

Chapter 3: Detailed analysis of Narcolepsy Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Narcolepsy Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Narcolepsy Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Narcolepsy Drug Industry Trends Table 2. Narcolepsy Drug Industry Drivers Table 3. Narcolepsy Drug Industry Opportunities and Challenges Table 4. Narcolepsy Drug Industry Restraints Table 5. Global Narcolepsy Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Narcolepsy Drug Revenue Share by Company (2021-2026) Table 7. Global Narcolepsy Drug Sales Volume by Company (Kg) & (2021-2026) Table 8. Global Narcolepsy Drug Sales Volume Share by Company (2021-2026) Table 9. Global Narcolepsy Drug Average Price (k USD/Kg) of Company (2021-2026) Table 10. Global Narcolepsy Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Narcolepsy Drug Key Company Manufacturing Base & Headquarters Table 12. Global Narcolepsy Drug Company, Product Type & Application Table 13. Global Narcolepsy Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Narcolepsy Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Antioxidants Type Table 18. Significant Companies of Stimulants Type Table 19. Significant Companies of Others Table 20. Global Narcolepsy Drug Sales Volume by Type 2021 VS 2025 VS 2032 (Kg) Table 21. Global Narcolepsy Drug Sales Volume by Type (2021-2026) & (Kg) Table 22. Global Narcolepsy Drug Sales Volume by Type (2027-2032) & (Kg) Table 23. Global Narcolepsy Drug Sales Volume Share by Type (2021-2026) Table 24. Global Narcolepsy Drug Sales Volume Share by Type (2027-2032) Table 25. Global Narcolepsy Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Narcolepsy Drug Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Narcolepsy Drug Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Narcolepsy Drug Sales Value Share by Type (2021-2026) Table 29. Global Narcolepsy Drug Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Daytime Extreme Sleepiness Table 31. Significant Companies of Cataplexia Table 32. Significant Companies of Others Table 33. Global Narcolepsy Drug Sales Volume by Application 2021 VS 2025 VS 2032 (Kg) Table 34. Global Narcolepsy Drug Sales Volume by Application (2021-2026) & (Kg) Table 35. Global Narcolepsy Drug Sales Volume by Application (2027-2032) & (Kg) Table 36. Global Narcolepsy Drug Sales Volume Share by Application (2021-2026) Table 37. Global Narcolepsy Drug Sales Volume Share by Application (2027-2032) Table 38. Global Narcolepsy Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Narcolepsy Drug Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Narcolepsy Drug Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Narcolepsy Drug Sales Value Share by Application (2021-2026) Table 42. Global Narcolepsy Drug Sales Value Share by Application (2027-2032) Table 43. Global Narcolepsy Drug Sales by Region: 2021 VS 2025 VS 2032 (Kg) Table 44. Global Narcolepsy Drug Sales by Region (2021-2026) & (Kg) Table 45. Global Narcolepsy Drug Sales Market Share by Region (2021-2026) Table 46. Global Narcolepsy Drug Sales by Region (2027-2032) & (Kg) Table 47. Global Narcolepsy Drug Sales Market Share by Region (2027-2032) Table 48. Global Narcolepsy Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Narcolepsy Drug Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Narcolepsy Drug Sales Value Share by Region (2021-2026) Table 51. Global Narcolepsy Drug Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Narcolepsy Drug Sales Value Share by Region (2027-2032) Table 53. Global Narcolepsy Drug Market Average Price (k USD/Kg) by Region (2021-2026) Table 54. Global Narcolepsy Drug Market Average Price (k USD/Kg) by Region (2027-2032) Table 55. Global Narcolepsy Drug Sales by Country: 2021 VS 2025 VS 2032 (Kg) Table 56. Global Narcolepsy Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Narcolepsy Drug Sales by Country (2021-2026) & (Kg) Table 58. Global Narcolepsy Drug Sales Market Share by Country (2021-2026) Table 59. Global Narcolepsy Drug Sales by Country (2027-2032) & (Kg) Table 60. Global Narcolepsy Drug Sales Market Share by Country (2027-2032) Table 61. Global Narcolepsy Drug Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Narcolepsy Drug Sales Value Market Share by Country (2021-2026) Table 63. Global Narcolepsy Drug Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Narcolepsy Drug Sales Value Market Share by Country (2027-2032) Table 65. Jazz Pharmaceuticals Company Information Table 66. Jazz Pharmaceuticals Business Overview Table 67. Jazz Pharmaceuticals Narcolepsy Drug Sales (Kg), Value (US$ Million), Price (k USD/Kg) and Gross Margin (2021-2026) Table 68. Jazz Pharmaceuticals Narcolepsy Drug Product Portfolio Table 69. Jazz Pharmaceuticals Recent Development Table 70. Teva Pharmaceutical Company Information Table 71. Teva Pharmaceutical Business Overview Table 72. Teva Pharmaceutical Narcolepsy Drug Sales (Kg), Value (US$ Million), Price (k USD/Kg) and Gross Margin (2021-2026) Table 73. Teva Pharmaceutical Narcolepsy Drug Product Portfolio Table 74. Teva Pharmaceutical Recent Development Table 75. Novartis Company Information Table 76. Novartis Business Overview Table 77. Novartis Narcolepsy Drug Sales (Kg), Value (US$ Million), Price (k USD/Kg) and Gross Margin (2021-2026) Table 78. Novartis Narcolepsy Drug Product Portfolio Table 79. Novartis Recent Development Table 80. Mylan Company Information Table 81. Mylan Business Overview Table 82. Mylan Narcolepsy Drug Sales (Kg), Value (US$ Million), Price (k USD/Kg) and Gross Margin (2021-2026) Table 83. Mylan Narcolepsy Drug Product Portfolio Table 84. Mylan Recent Development Table 85. Key Raw Materials Table 86. Raw Materials Key Suppliers Table 87. Narcolepsy Drug Distributors List Table 88. Narcolepsy Drug Customers List Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Narcolepsy Drug Product Image Figure 2. Global Narcolepsy Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Narcolepsy Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Narcolepsy Drug Sales (2021-2032) & (Kg) Figure 5. Global Narcolepsy Drug Sales Average Price (k USD/Kg) & (2021-2032) Figure 6. Global Narcolepsy Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Antioxidants Type Image Figure 10. Stimulants Type Image Figure 11. Others Image Figure 12. Global Narcolepsy Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (Kg) Figure 13. Global Narcolepsy Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Narcolepsy Drug Sales Volume Share by Type (2021-2032) Figure 15. Global Narcolepsy Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Narcolepsy Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Narcolepsy Drug Sales Value Share by Type (2021-2032) Figure 18. Daytime Extreme Sleepiness Image Figure 19. Cataplexia Image Figure 20. Others Image Figure 21. Global Narcolepsy Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (Kg) Figure 22. Global Narcolepsy Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Narcolepsy Drug Sales Volume Share by Application (2021-2032) Figure 24. Global Narcolepsy Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Narcolepsy Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Narcolepsy Drug Sales Value Share by Application (2021-2032) Figure 27. Global Narcolepsy Drug Sales by Region: 2021 VS 2025 VS 2032 (Kg) Figure 28. Global Narcolepsy Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Narcolepsy Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Narcolepsy Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Narcolepsy Drug Sales Value (2021-2032) & (US$ Million) Figure 32. North America Narcolepsy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Narcolepsy Drug Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Narcolepsy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Narcolepsy Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Narcolepsy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Narcolepsy Drug Sales Value (2021-2032) & (US$ Million) Figure 38. South America Narcolepsy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Narcolepsy Drug Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Narcolepsy Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Narcolepsy Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Narcolepsy Drug Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Narcolepsy Drug Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Antioxidants Type
  • Stimulants Type
  • Others
Applications
  • Daytime Extreme Sleepiness
  • Cataplexia
  • Others
Companies covered
  • Jazz Pharmaceuticals
  • Teva Pharmaceutical
  • Novartis
  • Mylan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Narcolepsy Drug Sales Value (2021-2032)
  4. 1.2.2 Global Narcolepsy Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Narcolepsy Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Narcolepsy Drug Market Dynamics
  1. 2.1 Narcolepsy Drug Industry Trends
  2. 2.2 Narcolepsy Drug Industry Drivers
  3. 2.3 Narcolepsy Drug Industry Opportunities and Challenges
  4. 2.4 Narcolepsy Drug Industry Restraints
3 Narcolepsy Drug Market by Company
  1. 3.1 Global Narcolepsy Drug Company Revenue Ranking in 2025
  2. 3.2 Global Narcolepsy Drug Revenue by Company (2021-2026)
  3. 3.3 Global Narcolepsy Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Narcolepsy Drug Average Price by Company (2021-2026)
  5. 3.5 Global Narcolepsy Drug Company Ranking (2024-2026)
  6. 3.6 Global Narcolepsy Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Narcolepsy Drug Company Product Type and Application
  8. 3.8 Global Narcolepsy Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Narcolepsy Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Narcolepsy Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Narcolepsy Drug Market by Type
  1. 4.1 Narcolepsy Drug Type Introduction
  2. 4.1.1 Antioxidants Type
  3. 4.1.2 Stimulants Type
  4. 4.1.3 Others
  5. 4.2 Global Narcolepsy Drug Sales Volume by Type
  6. 4.2.1 Global Narcolepsy Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Narcolepsy Drug Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Narcolepsy Drug Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Narcolepsy Drug Sales Value by Type
  10. 4.3.1 Global Narcolepsy Drug Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Narcolepsy Drug Sales Value by Type (2021-2032)
  12. 4.3.3 Global Narcolepsy Drug Sales Value Share by Type (2021-2032)
5 Narcolepsy Drug Market by Application
  1. 5.1 Narcolepsy Drug Application Introduction
  2. 5.1.1 Daytime Extreme Sleepiness
  3. 5.1.2 Cataplexia
  4. 5.1.3 Others
  5. 5.2 Global Narcolepsy Drug Sales Volume by Application
  6. 5.2.1 Global Narcolepsy Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Narcolepsy Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Narcolepsy Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Narcolepsy Drug Sales Value by Application
  10. 5.3.1 Global Narcolepsy Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Narcolepsy Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Narcolepsy Drug Sales Value Share by Application (2021-2032)
6 Narcolepsy Drug Regional Sales and Value Analysis
  1. 6.1 Global Narcolepsy Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Narcolepsy Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Narcolepsy Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Narcolepsy Drug Sales by Region (2027-2032)
  5. 6.3 Global Narcolepsy Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Narcolepsy Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Narcolepsy Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Narcolepsy Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Narcolepsy Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Narcolepsy Drug Sales Value (2021-2032)
  12. 6.6.2 North America Narcolepsy Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Narcolepsy Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Narcolepsy Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Narcolepsy Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Narcolepsy Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Narcolepsy Drug Sales Value (2021-2032)
  21. 6.9.2 South America Narcolepsy Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Narcolepsy Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Narcolepsy Drug Sales Value Share by Country, 2025 VS 2032
7 Narcolepsy Drug Country-level Sales and Value Analysis
  1. 7.1 Global Narcolepsy Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Narcolepsy Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Narcolepsy Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Narcolepsy Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Narcolepsy Drug Sales by Country (2027-2032)
  6. 7.4 Global Narcolepsy Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Narcolepsy Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Narcolepsy Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Narcolepsy Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Narcolepsy Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Narcolepsy Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Jazz Pharmaceuticals
  2. 8.1.1 Jazz Pharmaceuticals Company Information
  3. 8.1.2 Jazz Pharmaceuticals Business Overview
  4. 8.1.3 Jazz Pharmaceuticals Narcolepsy Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Jazz Pharmaceuticals Narcolepsy Drug Product Portfolio
  6. 8.1.5 Jazz Pharmaceuticals Recent Developments
  7. 8.2 Teva Pharmaceutical
  8. 8.2.1 Teva Pharmaceutical Company Information
  9. 8.2.2 Teva Pharmaceutical Business Overview
  10. 8.2.3 Teva Pharmaceutical Narcolepsy Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Teva Pharmaceutical Narcolepsy Drug Product Portfolio
  12. 8.2.5 Teva Pharmaceutical Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Narcolepsy Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Narcolepsy Drug Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Narcolepsy Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Narcolepsy Drug Product Portfolio
  24. 8.4.5 Mylan Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Narcolepsy Drug Value Chain Analysis
  2. 9.1.1 Narcolepsy Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Narcolepsy Drug Sales Mode & Process
  6. 9.2 Narcolepsy Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Narcolepsy Drug Distributors
  9. 9.2.3 Narcolepsy Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst